phenoxybenzamine has been researched along with 1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid)-2-(o-ethyl-tyr)-4-val-arginine vasopressin in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Matsuda, T; Mori, M; Tsushima, H | 1 |
1 other study(ies) available for phenoxybenzamine and 1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid)-2-(o-ethyl-tyr)-4-val-arginine vasopressin
| Article | Year |
|---|---|
Microinjections of angiotensin II into the supraoptic and paraventricular nuclei produce potent antidiureses by vasopressin release mediated through adrenergic and angiotensin receptors.
Topics: Analysis of Variance; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Arginine Vasopressin; Diuresis; Dose-Response Relationship, Drug; Injections, Intra-Arterial; Injections, Intraventricular; Male; Microinjections; Paraventricular Hypothalamic Nucleus; Phenoxybenzamine; Rats; Rats, Wistar; Receptors, Adrenergic, alpha; Receptors, Adrenergic, beta; Receptors, Angiotensin; Supraoptic Nucleus; Timolol; Vasoconstriction; Vasopressins | 1994 |